Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308773 | 0.84 | FGFR1 (1.00) | FGFR1ALDH1A1HTTMAPTHPGD | |
| SCHEMBL29449347 | 0.84 | FGFR1 (1.00) | FGFR1ALDH1A1HTTMAPTHPGD | |
| SCHEMBL30402227 | 0.83 | HTT (0.88) | FGFR1ALDH1A1HTTMAPT | |
| SCHEMBL3419279 | 0.83 | HTT (0.88) | FGFR1ALDH1A1HTTMAPT | |
| SCHEMBL19911376 | 0.82 | FGFR1 (1.00) | FGFR1ALDH1A1HTTMAPTHPGD | |
| SCHEMBL3342620 | 0.82 | ALDH1A1 (1.00) | FGFR1ALDH1A1HTTMAPTHPGD | |
| SCHEMBL19459554 | 0.81 | ALDH1A1 (0.60) | FGFR1ALDH1A1HTTMAPT | |
| SCHEMBL5108449 | 0.81 | FGFR1 (0.61) | FGFR1ALDH1A1HTTMAPTHPGD | |
| SCHEMBL5107674 | 0.81 | FGFR1 (0.57) | FGFR1ALDH1A1HTTMAPTHPGD | |
| SCHEMBL19350754 | 0.80 | FGFR1 (0.62) | FGFR1ALDH1A1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114133380-B | Purpurin derivative electrochromism and electroluminescent photochromic material, and preparation method and application thereof | 华南理工大学 | 2022-12-16 | — | — | CN | claimed |
| CN-114133380-A | Purpurin derivative electrochromism and electroluminescent photochromic material, and preparation method and application thereof | 华南理工大学 | 2022-03-04 | — | — | CN | claimed |
| EP-3424924-B1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| CN-114133380-B | Purpurin derivative electrochromism and electroluminescent photochromic material, and preparation method and application thereof | 华南理工大学 | 2022-12-16 | — | — | CN | disclosed |
| CN-109071523-B | Urea compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-114133380-A | Purpurin derivative electrochromism and electroluminescent photochromic material, and preparation method and application thereof | 华南理工大学 | 2022-03-04 | — | — | CN | disclosed |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-02-14 | — | — | US | disclosed |
| EP-3424924-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2019-01-09 | — | — | EP | disclosed |
| CN-109071523-A | Urea compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-107176951-A | A kind of carbamide compounds, its preparation method and its medical usage | 恩瑞生物医药科技（上海）有限公司 | 2017-09-19 | — | — | CN | disclosed |
| WO-2017152874-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 恩瑞生物医药科技（上海）有限公司 | 2017-09-14 | — | — | WO | disclosed |
| EP-0946508-B1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-09-23 | — | — | EP | disclosed |
| US-6548512-B1 | Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-6218388-B1 | THERAPY OF PROTEIN TYROSINE KINASE MEDIATED CANCER, ATHEROSCLEROSIS, RESTENOSIS, AND PSORIASIS BY ADMINISTERING BENZIMIDAZOLE DERIVATIVE | WARNER-LAMBERT COMPANY | 2001-04-17 | — | — | US | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| US-5990146-A | TREATING PROTEIN TYROSINE KINASE MEDIATED CANCER; ANTICARCINOGENIC AGENTS; ATHEROSCLEROSIS; RESTENOSIS; PSORIASIS; ANTIPROLIFERATIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-11-23 | — | — | US | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047964-A1 | UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FLT3, WEE1, SLC14A1 | FGFR1 294/4885ALDH1A1 2478/4885HTT 3467/4885 |
| US-10647680-B2 | Urea compound, preparation method therefor and medical use thereof | FLT3, WEE1, SLC14A1 | FGFR1 294/4885ALDH1A1 2478/4885HTT 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.